PD 3044Alternative Names: PD-3044
Latest Information Update: 21 Jul 2016
At a glance
- Originator P2D Bioscience
- Class Tropanes
- Mechanism of Action Dopamine receptor agonists; Dopamine uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Attention-deficit hyperactivity disorder
Most Recent Events
- 21 Jul 2016 Preclinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)